Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.
Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., Xu, T., Zhou, A.(2017) Cell Discov 3: 17004-17004
- PubMed: 28280600 
- DOI: 10.1038/celldisc.2017.4
- Primary Citation of Related Structures:  
- PubMed Abstract: 
The use of antibodies to target immune checkpoints, particularly PD-1/PD-L1, has made a profound impact in the field of cancer immunotherapy. Here, we identified KN035, an anti-PD-L1 nanobody that can strongly induce T-cell responses and inhibit tumo ...